Expression of CCCTC‐binding factor (CTCF) is linked to poor prognosis in prostate cancer-Reference-Cited by-同舟云学术

Expression of CCCTC‐binding factor (CTCF) is linked to poor prognosis in prostate cancer

Published:2019-11-29 Issue:1 Volume:14 Page:129-138
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Höflmayer Doris¹,Steinhoff Amélie¹,Hube‐Magg Claudia¹,Kluth Martina¹,Simon Ronald¹^ORCID,Burandt Eike¹,Tsourlakis Maria Christina¹,Minner Sarah¹,Sauter Guido¹,Büscheck Franziska¹,Wilczak Waldemar¹,Steurer Stefan¹,Huland Hartwig²,Graefen Markus²,Haese Alexander²,Heinzer Hans²,Schlomm Thorsten³,Jacobsen Frank¹,Hinsch Andrea¹,Poos Alexandra M.⁴⁵⁶⁷,Oswald Marcus⁴⁵,Rippe Karsten⁷,König Rainer⁴⁵,Schroeder Cornelia⁸

Affiliation:

1. Institute of Pathology University Medical Center Hamburg‐Eppendorf Germany

2. Martini‐Clinic Prostate Cancer Center University Medical Center Hamburg‐Eppendorf Germany

3. Department of Urology Charité ‐ Universitätsmedizin Berlin Germany

4. Integrated Research and Treatment Center Center for Sepsis Control and Care (CSCC) Jena University Hospital Germany

5. Network Modeling Leibniz Institute for Natural Product Research and Infection Biology ‐ Hans Knöll Institute Jena Germany

6. Faculty of Biosciences Heidelberg University Germany

7. Division of Chromatin Networks German Cancer Research Center (DKFZ) and Bioquant Heidelberg Germany

8. General, Visceral and Thoracic Surgery Department and Clinic University Medical Center Hamburg‐Eppendorf Germany

Funder

Bundesministerium für Bildung und Forschung

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12597

Reference42 articles.

1. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

3. CHD1 Is a 5q21 Tumor Suppressor Required for ERG Rearrangement in Prostate Cancer

4. Genome Organization Drives Chromosome Fragility

5. Systematic enrichment analysis of potentially functional regions for 103 prostate cancer risk-associated loci

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SWI/SNF chromatin remodelers in prostate cancer progression;Frontiers in Epigenetics and Epigenomics;2024-01-04

2. Identification of common factors among fibrosarcoma, rhabdomyosarcoma, and osteosarcoma by network analysis;Biosystems;2024-01

3. Identifying Cancer Type-Specific Transcriptional Programs through Network Analysis;Cancers;2023-08-18

4. Identification of common factors among Fibrosarcoma, Rhabdomyosarcoma, and Osteosarcoma by network analysis;2023-04-12

5. Associations of CTCF and FOXA1 with androgen and IGF pathways in men with localized prostate cancer;Growth Hormone & IGF Research;2023-04